213 related articles for article (PubMed ID: 21550231)
1. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
Alifrangis C; Krell J; Stebbing J
Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
[No Abstract] [Full Text] [Related]
2. Health reform accelerates changes in the pharmaceutical industry.
Spatz ID
Health Aff (Millwood); 2010 Jul; 29(7):1331-6. PubMed ID: 20606183
[TBL] [Abstract][Full Text] [Related]
3. Considerations in the pharmacoeconomics of glaucoma.
Hirsch JD
Manag Care; 2002 Nov; 11(11 Suppl):32-7. PubMed ID: 15357537
[TBL] [Abstract][Full Text] [Related]
4. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
6. [Pharmacoeconomics--survey and status].
Pedersen KM
Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomics: determining the value of drug therapy.
Peterson C
Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
[No Abstract] [Full Text] [Related]
8. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
Henry D; Taylor C
Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness data on biologics needed.
Sheridan C; Katsnelson A
Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
[No Abstract] [Full Text] [Related]
10. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
11. A few specialty drug prices fall--all generics.
Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
[No Abstract] [Full Text] [Related]
12. Lowering Part D drug costs without direct CMS negotiations.
Sipkoff M
Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
[No Abstract] [Full Text] [Related]
13. Drug therapy: safety, effectiveness, and economics.
Brandys J
Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
[TBL] [Abstract][Full Text] [Related]
14. Should drug prices be negotiated under part D of Medicare? And if so, how?
Frank RG; Newhouse JP
Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomics comes of age?
Walley T; Breckenridge A
Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
[TBL] [Abstract][Full Text] [Related]
16. How insurers' bargaining power affects drug prices in Medicare Part D.
Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
[No Abstract] [Full Text] [Related]
17. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
18. Eliminating innovation: how price controls limit access.
Ingram J
J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
[No Abstract] [Full Text] [Related]
19. Examining the link between price regulation and pharmaceutical R&D investment.
Vernon JA
Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics: historical perspective.
Bootman JL; McGhan WF; Townsend RJ
Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
